Q1 EPS Forecast for Turnstone Biologics Decreased by Analyst

Turnstone Biologics Corp. (NASDAQ:TSBX) – Stock analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for Turnstone Biologics in a research note issued on Tuesday, April 1st. Leerink Partnrs analyst D. Graybosch now forecasts that the company will earn ($0.26) per share for the quarter, down from their prior forecast of ($0.20). The consensus estimate for Turnstone Biologics’ current full-year earnings is ($3.32) per share. Leerink Partnrs also issued estimates for Turnstone Biologics’ Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.69) EPS and FY2026 earnings at ($0.51) EPS.

Turnstone Biologics (NASDAQ:TSBX) last announced its quarterly earnings data on Friday, March 28th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.13.

Separately, Piper Sandler lowered shares of Turnstone Biologics from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $3.75 to $0.40 in a research note on Wednesday, February 5th.

Turnstone Biologics Trading Down 0.7 %

Shares of TSBX stock opened at $0.38 on Thursday. The firm has a fifty day moving average price of $0.41 and a 200 day moving average price of $0.47. The company has a market cap of $8.72 million, a P/E ratio of -0.12 and a beta of 2.04. Turnstone Biologics has a 12 month low of $0.34 and a 12 month high of $3.88.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Turnstone Biologics stock. Takeda Pharmaceutical Co. Ltd. purchased a new position in shares of Turnstone Biologics Corp. (NASDAQ:TSBX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 895,824 shares of the company’s stock, valued at approximately $448,000. Turnstone Biologics comprises approximately 1.7% of Takeda Pharmaceutical Co. Ltd.’s holdings, making the stock its 8th biggest position. Takeda Pharmaceutical Co. Ltd. owned about 3.87% of Turnstone Biologics at the end of the most recent quarter. Hedge funds and other institutional investors own 52.51% of the company’s stock.

About Turnstone Biologics

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.